TG Therapeutics ups guidance

 

TG Therapeutics posts Q1 2026 EPS $0.12, revenue $204.9M, beats BRIUMVI guidance and raises 2026 outlook

• Q1 2026 non-GAAP EPS was $0.12 (+300% YoY) on revenue of $204.9M (+70% YoY).
• Q1 2026 results missed EPS expectations but exceeded revenue estimates versus analyst consensus.
• Q1 U.S. BRIUMVI revenue of $195M beat $185–190M guidance, growing 63% YoY.
• Total Q1 revenue reached $205M, with $201M from BRIUMVI product sales globally.
• Operating income rose to $34.8M and EPS to $0.12, both sharply up YoY.
• U.S. BRIUMVI full-year guidance raised to $885–900M; global revenue guided to ~$925M.
• Q2 U.S. BRIUMVI revenue guided to ~$220M, implying continued strong sequential growth.
• Over 25,000 patients have been prescribed BRIUMVI globally, with persistence exceeding initial expectations.
• BRIUMVI now leads CD20 dynamic share in infusion-capable private practices, benefiting from 1-hour infusions.
• ENHANCE Phase III single-dose IV regimen and subcutaneous Phase I data expected in coming weeks.
• Subcutaneous BRIUMVI Phase III fully enrolled; top-line around year-end with potential 2028 launch.
• Company repurchased $100M of stock in Q1 and expanded Blue Owl facility, boosting cash to $573M.
• Main concern: Execution and differentiation amid intensifying MS competition and dependence on successful subcutaneous/ENHANCE outcomes.
• Strong quarter, driven by BRIUMVI revenue outperformance, better-than-expected persistence, and a sizable guidance raise.

https://finviz.com/quote?t=TGTX&p=d